Reactive arthritis following COVID-19 current evidence, diagnosis, and management strategies.
COVID-19
Immunity
Reactive arthritis
Journal
Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112
Informations de publication
Date de publication:
15 Mar 2023
15 Mar 2023
Historique:
received:
30
12
2022
accepted:
25
02
2023
entrez:
16
3
2023
pubmed:
17
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
Immune-mediated conditions associated to Corona Virus Disease-19 (COVID-19) have been reported, including vasculitis, antiphospholipid antibody syndrome, myositis, and lupus. Emerging studies have reported the potential occurrence of reactive arthritis in patients previously infected with COVID-19. This systematic review summarised the current evidence on the occurrence of reactive arthritis in patients previously infected by COVID-19. This study was conducted according to the 2020 PRISMA guidelines. All the clinical investigations describing the occurrence of reactive arthritis following COVID-19 were accessed. In September 2022, the following databases were accessed: PubMed, Web of Science, Google Scholar, Embase. The generalities of the study were extracted: author, year and journal of publication, country of the main author, study design, sample size, mean age, number of women, main results of the study. The following data on COVID-19 severity and management were retrieved: type of treatment, hospitalization regimes (inpatient or outpatient), admission to the intensive care unit, need of mechanical ventilation, pharmacological management. The following data on reactive arthritis were collected: time elapsed between COVID-19 infection to the onset of reactive arthritis symptoms (days), pharmacological management, type of arthritis (mono- or bilateral, mono- or polyarticular), extra-articular manifestations, presence of tenosynovitis or enthesitis, synovial examination at microscopic polarised light, imaging (radiography, magnetic resonance, sonography), clinical examination, laboratory findings. Data from 27 case reports (54 patients) were retrieved, with a mean age of 49.8 ± 14.5 years. 54% (29 of 54 patients) were women. The mean time span between COVID-19 infection and the occurrence of reactive arthritis symptoms was 22.3 ± 10.7 days. Between studies diagnosis and management of reactive arthritis were heterogeneous. Symptoms resolved within few days in all studies considered. At last follow-up, all patients were minimally symptomatic or asymptomatic, and no additional therapy or attentions were required by any patient. Poor evidence suggests that COVID-19 could target the musculoskeletal system causing reactive arthritis at its post infectious stage. COVID-19 can act as a causative agent or as a trigger for development of reactive arthritis even without presence of antibodies of rheumatological disorders. Treating physicians should have a high index of suspicion while treating post infectious COVID-19 patient with arthralgia. Level IV, systematic review.
Sections du résumé
BACKGROUND
BACKGROUND
Immune-mediated conditions associated to Corona Virus Disease-19 (COVID-19) have been reported, including vasculitis, antiphospholipid antibody syndrome, myositis, and lupus. Emerging studies have reported the potential occurrence of reactive arthritis in patients previously infected with COVID-19. This systematic review summarised the current evidence on the occurrence of reactive arthritis in patients previously infected by COVID-19.
METHODS
METHODS
This study was conducted according to the 2020 PRISMA guidelines. All the clinical investigations describing the occurrence of reactive arthritis following COVID-19 were accessed. In September 2022, the following databases were accessed: PubMed, Web of Science, Google Scholar, Embase. The generalities of the study were extracted: author, year and journal of publication, country of the main author, study design, sample size, mean age, number of women, main results of the study. The following data on COVID-19 severity and management were retrieved: type of treatment, hospitalization regimes (inpatient or outpatient), admission to the intensive care unit, need of mechanical ventilation, pharmacological management. The following data on reactive arthritis were collected: time elapsed between COVID-19 infection to the onset of reactive arthritis symptoms (days), pharmacological management, type of arthritis (mono- or bilateral, mono- or polyarticular), extra-articular manifestations, presence of tenosynovitis or enthesitis, synovial examination at microscopic polarised light, imaging (radiography, magnetic resonance, sonography), clinical examination, laboratory findings.
RESULTS
RESULTS
Data from 27 case reports (54 patients) were retrieved, with a mean age of 49.8 ± 14.5 years. 54% (29 of 54 patients) were women. The mean time span between COVID-19 infection and the occurrence of reactive arthritis symptoms was 22.3 ± 10.7 days. Between studies diagnosis and management of reactive arthritis were heterogeneous. Symptoms resolved within few days in all studies considered. At last follow-up, all patients were minimally symptomatic or asymptomatic, and no additional therapy or attentions were required by any patient.
CONCLUSION
CONCLUSIONS
Poor evidence suggests that COVID-19 could target the musculoskeletal system causing reactive arthritis at its post infectious stage. COVID-19 can act as a causative agent or as a trigger for development of reactive arthritis even without presence of antibodies of rheumatological disorders. Treating physicians should have a high index of suspicion while treating post infectious COVID-19 patient with arthralgia.
LEVEL OF EVIDENCE
METHODS
Level IV, systematic review.
Identifiants
pubmed: 36922870
doi: 10.1186/s13018-023-03651-6
pii: 10.1186/s13018-023-03651-6
pmc: PMC10017067
doi:
Substances chimiques
Antibodies
0
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
205Informations de copyright
© 2023. The Author(s).
Références
Lancet Rheumatol. 2021 May;3(5):e324-e325
pubmed: 33748780
Curr Rheumatol Rev. 2020;16(1):2-8
pubmed: 31393253
Clin Infect Dis. 2020 Nov 19;71(16):2272-2275
pubmed: 32407466
Nat Rev Rheumatol. 2019 Aug;15(8):491-501
pubmed: 31227819
Curr Rheumatol Rep. 2020 May 26;22(7):29
pubmed: 32458153
Immun Inflamm Dis. 2021 Sep;9(3):628-631
pubmed: 33979033
Rheumatology (Oxford). 2021 Jan 5;60(1):479-480
pubmed: 33206974
Clin Rheumatol. 2018 Apr;37(4):869-874
pubmed: 29455267
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
J Clin Rheumatol. 2020 Sep;26(6):233
pubmed: 32694352
Nat Rev Immunol. 2020 Jun;20(6):345-346
pubmed: 32358580
Int Immunol. 2021 Sep 25;33(10):515-519
pubmed: 33715009
Best Pract Res Clin Rheumatol. 2011 Jun;25(3):347-57
pubmed: 22100285
Clin Rheumatol. 2021 Jul;40(7):2611-2619
pubmed: 33733315
Clin Rheumatol. 2021 Aug;40(8):3357-3362
pubmed: 33587197
J R Coll Physicians Edinb. 2021 Sep;51(3):288-297
pubmed: 34528623
Best Pract Res Clin Rheumatol. 2014 Dec;28(6):935-59
pubmed: 26096095
Best Pract Res Clin Rheumatol. 2004 Oct;18(5):689-703
pubmed: 15454127
Am Fam Physician. 1999 Aug;60(2):499-503, 507
pubmed: 10465225
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Cureus. 2020 Aug 12;12(8):e9698
pubmed: 32923288
Rheum Dis Clin North Am. 2009 Feb;35(1):21-44
pubmed: 19480995
Clin Exp Rheumatol. 2021 Jan-Feb;39 Suppl 128(1):25-26
pubmed: 33506755
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Rheumatology (Oxford). 2000 Apr;39(4):360-8
pubmed: 10817767
Clin Microbiol Rev. 2004 Apr;17(2):348-69
pubmed: 15084505
Autoimmun Rev. 2014 Apr-May;13(4-5):546-9
pubmed: 24418301
Reumatol Clin. 2023 Feb;19(2):67-73
pubmed: 35578636
Expert Opin Pharmacother. 2004 Jan;5(1):61-70
pubmed: 14680436
Lancet. 2011 Jun 18;377(9783):2127-37
pubmed: 21684383
Am J Med Sci. 2006 Aug;332(2):90-92
pubmed: 16909057
Lancet Rheumatol. 2020 Nov;2(11):e655-e657
pubmed: 33043303
Infect Dis Clin North Am. 2017 Jun;31(2):265-277
pubmed: 28292540
RMD Open. 2020 Aug;6(2):
pubmed: 32763956
Ann Rheum Dis. 2020 Aug 4;:
pubmed: 32753423
Medicine (Baltimore). 2021 Jun 11;100(23):e26089
pubmed: 34114992
Trop Dis Travel Med Vaccines. 2021 Jun 15;7(1):18
pubmed: 34130744
Biosci Rep. 2020 Feb 28;40(2):
pubmed: 32039436
Rheumatol Adv Pract. 2021 Feb 04;5(1):rkab001
pubmed: 33615130
Cureus. 2022 Apr 13;14(4):e24096
pubmed: 35573487
Rheumatol Int. 2021 Nov;41(11):2031-2039
pubmed: 34550429
Front Immunol. 2020 Jun 16;11:1441
pubmed: 32612615
Scand J Rheumatol Suppl. 1995;101:213-7
pubmed: 7747130
Reumatismo. 2021 Apr 19;73(1):59-63
pubmed: 33874649
Reumatol Clin (Engl Ed). 2019 Mar - Apr;15(2):113-116
pubmed: 28751110
Rheumatology (Oxford). 2021 Jul 1;60(7):e232-e233
pubmed: 33471106
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Cureus. 2020 Nov 28;12(11):e11761
pubmed: 33409010
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Int J Mol Sci. 2020 Jul 23;21(15):
pubmed: 32718086
Cell Rep. 2019 Feb 5;26(6):1585-1597.e4
pubmed: 30726740
Acta Reumatol Port. 2020 Oct-Dec;45(4):278-280
pubmed: 33420769
Nat Rev Rheumatol. 2021 Feb;17(2):71-72
pubmed: 33339986
Rheumatology (Oxford). 2000 Feb;39(2):117-9
pubmed: 10725059
Case Rep Rheumatol. 2021 Apr 26;2021:6610340
pubmed: 33986966
Ann Rheum Dis. 2021 Jun;80(6):e101
pubmed: 32591356
J Med Virol. 2021 Jan;93(1):192-193
pubmed: 32652541
BMJ Case Rep. 2021 Mar 2;14(3):
pubmed: 33653867
J Adolesc Health. 2009 Apr;44(4):309-15
pubmed: 19306788
Best Pract Res Clin Rheumatol. 2003 Apr;17(2):219-39
pubmed: 12787523